

ASX ANNOUNCEMENT

14 June 2021

ADAPT[®] CONDUIT PROOF OF CONCEPT STUDY FINDS NO CALCIFICATION

Brisbane, Australia and Minneapolis, USA.

Anteris Technologies Ltd (ASX: AVR; Anteris or the Company) announces the successful completion of its Proof of Concept (POC) animal study testing the viability of ADAPT[®] treated conduits in the carotid artery.

The conduits treated with the ADAPT[®] process showed no evidence of calcification, as indicated by histopathology.

Moreover, there were no visible signs of inflammation, specifically in the intimal or medial layers of the conduits. The grafts also showed the presence of a partial neo-intimal layer, likely indicating surface remodeling of the vessels.

Previous attempts by investigators to use animal vessels in this setting failed due to heavy calcification deposits occurring whereas none were shown here with the ADAPT[®] treated conduits.

“This marks a major step forward for ADAPT[®] treated prosthetic conduits for use in CABG surgeries. The global CABG market was estimated at approximately \$US500 million for 2021 with a 5.3% CAGR out to 2026 and where there are very few viable alternatives (other than harvesting a patient’s own saphenous vein) for the by-pass graft. Not only does this further validate ADAPT[®]’s superior anti-calcification properties in highly problematic areas of surgery, it pushes Anteris closer to a viable alternative for patients of coronary by-pass (CABG) surgery.” Wayne Paterson, Anteris’ Chief Executive Officer remarked.

“We are extremely encouraged by these results in a historically difficult setting prone to calcification, associated inflammatory responses and intimal hyperplasia which results in high failure rates,” Professor Leon Neethling (Anteris Vice President, Cardiovascular Technologies, and the principal investigator) commented.

The study used bovine carotid and mesenteric arteries as the conduits to test the viability of Adapt treated conduits in the carotid artery (as a proxy for CABG) in sheep. These conduits ranged from 2.5mm to 3.8mm in diameter and one six to seven cm length was implanted per animal.

Based on these results, Anteris plans to start a larger animal study in Australia during 2021 implanting the conduit into the CABG position.

ENDS

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT® tissue technology, paired with DurAVR™'s unique 3D single-piece aortic valve design, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Ms Kyahn Williamson

WE Communications

E: WE-AUAnterisTech@we-worldwide.com

P: +61 401 018 828

www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech